Events

Investors



Corporate Profile

Rigel currently has the following product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

Recent News

More »
DateTitle 
05/05/16Rigel to Present at Upcoming American Association of Immunologists (AAI) Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 5, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present three scientific posters at the American Association of Immunologists (AAI) meeting in Seattle, Washington from May 13-17, 2016.  The posters provide data from the company's preclinical research programs in key anti-inflammatory and autoimmune targets, Nrf2, MerTK and IRAK1/4. Rigel plans to partner select preclinical research programs in the future. An ove... 
Printer Friendly Version
05/03/16Rigel Announces First Quarter 2016 Financial Results
- Conference Call and Webcast Today at 5:00 PM Eastern Time - SOUTH SAN FRANCISCO, Calif., May 3, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2016. "We look forward to our upcoming Phase 3 data as we continue with our planning for the potential commercial launch of fostamatinib in the United States," said Raul Rodriguez, president and chief executive officer of Rigel.  "Also, we initiated the Phase ... 
Printer Friendly Version
04/26/16Rigel Announces Conference Call and Webcast to Report First Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., April 26, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2016 financial results after market close on Tuesday, May 3, 2016.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results. Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-2939 (... 
Printer Friendly Version

Upcoming Events

More »

There are currently no events scheduled.

Stock Quote

RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$2.54
Change (%) + 0.03 (1.20%)
Volume337,925
Data as of 05/25/16 4:00 p.m. ET   Refresh quote

Stock Chart

Stock chart for: RIGL.O.  Currently trading at $2.54 with a 52 week high of $3.78 and a 52 week low of $1.88.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

E-mail Alerts

Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.